Thanks Swegen, I appreciate all of your efforts to counter some of the FUD that is being spread on this board, and on Twitter.
I believe that there is a deliberate coordinated and concerted attempt by some here to control the narrative, and steer the discussions here towards meaningless, make-believe problems.
AF was insinuating that NWBio did not have a patent that covers combination trials with DCVax-L plus a checkpoint inhibitor. I posted the link to the patent application for DCVax plus a checkpoint inhibitor. That patent application is still pending, and it has not been granted yet.
AF was also saying that UCLA was not working with NWBio anymore, and the combination trial with the autologous tumor lysate (ATL) dendritic cell (DC) vaccine and Pembrolizumab (Keytruda) does not involve DCVax-L. However, this argument was refuted by several posts on this board, including some posts by me, Dr. Bala and sentiment_stocks. I have included the slide that Dr. Liau used at UAB, and other presentations, that clearly shows that UCLA is using DCVax-L in combination with a PD-1 inhibitor (Keytruda/Pembrolizumab)below:
Here are some links to a few of those message posts:
News 
Market Data 
Discover 
AI
